Samba O Sow, Milagritos D Tapia, Fadima C Haidara, Fatoumata Diallo, Xi Han, Jingjing Chen, Lei Shi, Qing Yang, Bangwei Yu, Yalin Hu, Lin Yuan, Ge Liu, Silvia Grappi, Martina Monti, Simonetta Viviani, Min Ji, Chenliang Zhou
OBJECTIVES: ZR-202-CoV and ZR-202a-CoV are novel recombinant vaccines containing 25 µg of the prototype (Wuhan strain) or B.1.351 strain (Beta variant) SARS-CoV-2 S-protein expressed in CHO cells, respectively, adjuvanted with Al(OH)3 and CpG-ODN. We assessed their safety and immunogenicity in this Phase I, randomized, observer-blind, controlled study in Mali. DESIGN: Sixty healthy 18-55-year-old adults randomized 1:1:1 received two doses of ZR-202-CoV, ZR-202a-CoV, or Comirnaty® 28 days apart...
September 11, 2024: International Journal of Infectious Diseases: IJID